11 studies found for:    Open Studies | "Carcinoma, Merkel Cell"
Show Display Options
Rank Status Study
1 Recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Merkel Cell Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
2 Recruiting Study of aNK (Activated NK-92, Formerly Neukoplast) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)
Conditions: Stage IIIB Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma
Intervention: Biological: aNK
3 Recruiting MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Drug: MLN0128
4 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
5 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
6 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
7 Recruiting Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Condition: Carcinoma, Merkel Cell
Intervention: Drug: Lanreotide
8 Recruiting Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Polyomavirus Infection;   Stage IV Merkel Cell Carcinoma
Interventions: Drug: Avelumab;   Other: Laboratory Biomarker Analysis;   Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells;   Radiation: Radiation Therapy;   Biological: Recombinant Interferon Beta
9 Recruiting Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Conditions: Dermatologic Conditions;   Healthy Volunteers;   Normal Volunteers;   Carcinoma, Merkel Cell
Intervention:
10 Recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
11 Not yet recruiting A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
Conditions: Head and Neck Squamous Cell Carcinoma;   Breast Cancer;   Sarcoma;   Merkel Cell Carcinoma;   Cutaneous T-Cell Lymphoma;   Melanoma;   Renal Cancer;   Bladder Cancer;   Prostate Cancer
Interventions: Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Poly ICLC

Indicates status has not been verified in more than two years